Method of diagnosing bladder cancer

Patent metadata

Field	Value
Publication number	US-12529110-B2
Application number	US-202217571248-A
Country	US
Kind code	B2
Filing date	Jan 7, 2022
Priority date	Apr 20, 2009
Publication date	Jan 20, 2026
Grant date	Jan 20, 2026

Abstract

The present invention relates to a method of diagnosing cancer in a subject comprising detecting in the DNA of said subject at least one hypermethylated CpG island associated with said cancer, wherein an elevation in the level of methylation in said CpG island of said subject, relative to the level of methylation in said CpG island of a control subject, is indicative of said CpG island being hypermethylated.

First claim

We claim:

1 . A method comprising:
a. obtaining a nucleic acid sample isolated from a urine cell fraction of a subject at risk of or suffering from non-muscle invasive (NMI) bladder cancer; and b. detecting an increased level of methylation of at least one CpG island of ONECUT2 in the sample located between chr18:53259508 and chr 18:53259552.

2 . The method of claim 1 , wherein detecting comprises detecting the level of methylation of at least three CpG dinucleotides in the at least one CpG island of ONECUT2.

3 . A method for diagnosing non-muscle invasive (NMI) bladder cancer in a subject at risk of, or suffering from, NMI bladder cancer comprising:
a. measuring DNA methylation levels of at least one CpG island in ONECUT2 in a urine sample from the subject; b. comparing the level of methylation of the at least one CpG island from the urine sample of the subject to the level of methylation of the at least one CpG sequence of ONECUT2 from a urine sample from a healthy control subject; and c. detecting an increase in the level of methylation of the at least one CpG island in the urine sample of the subject relative to the urine sample from the healthy control subject, thereby diagnosing the subject as having NMI bladder cancer and performing a cystoscopy and/or transurethral resection on the subject.

4 . The method of claim 3 , wherein the step of measuring DNA methylation levels is preceded by the step of extracting DNA from a urine cell fraction obtained from the urine sample.

5 . The method of claim 4 , wherein the urine cell fraction is obtained by filtration or centrifugation of the urine sample.

6 . The method of claim 4 , wherein the method further comprises the step of obtaining the cell fraction by filtration or centrifugation of the urine sample.

7 . The method of claim 3 , wherein the subject is tested for the presence or absence of an FGFR3 gene mutation.

8 . A method for predicting the recurrence or progression of a non-muscle invasive (NMI) bladder cancer in a subject at risk of, or suffering from NMI bladder cancer comprising:
a. measuring DNA methylation levels of at least one CpG island in ONECUT2 in a urine sample from the subject; b. comparing the level of methylation of the at least one CpG island from the urine sample of the subject to the level of methylation of the at least one CpG sequence of ONECUT2 from a urine sample from a healthy control subject; and c. detecting an increase in the level of methylation of the at least one CpG island in the urine sample of the subject relative to the urine sample from the healthy control subject, whereby an increase in the level of methylation of the at least one CpG island in the urine sample of the subject relative to the urine sample from the healthy control subject indicates that the NMI bladder cancer in the subject is likely to progress or recur and performing a cystoscopy and/or transurethral resection on the subject.

9 . The method of claim 8 , wherein the urine sample is a urine cell fraction.

10 . The method of claim 9 , wherein the urine cell fraction is obtained by filtration or centrifugation.

11 . The method of claim 8 , wherein the subject is tested for the presence or absence of an FGFR3 gene mutation.

12 . The method of claim 1 , wherein the urine cell fraction is obtained by filtration or centrifugation.

13 . The method of claim 3 , wherein the at least one CpG island of ONECUT2 is located between chr18:53254153 and chr 18:53259851.

14 . The method of claim 3 , wherein the at least one CpG island of ONECUT2 is located between chr18:53259508 and chr 18:53259552.

15 . The method of claim 1 , wherein detecting an increased level of methylation of the at least one CpG island of ONECUT2 comprises treating the nucleic acid sample with sodium bisulfite under conditions whereby unmethylated cytosines are converted to uracil, and methylated cytosines remain unchanged and performing methylation-specific PCR (MSP) on the treated nucleic acid using at least two distinct methylation-specific primer sets for the sequence of ONECUT2.

16 . The method of claim 1 , wherein detecting an increased level of methylation of the at least one CpG island of ONECUT2 comprises reacting the nucleic acid sample with reagents for detecting the level of methylation of at least one CpG island of ONECUT2 and performing a polymerase chain reaction (PCR).

17 . A method comprising:
a. obtaining a nucleic acid sample isolated from a bladder biopsy of a subject at risk of or suffering from non-muscle invasive (NMI) bladder cancer; and b. detecting an increased level of methylation of at least one CpG island of ONECUT2 in the sample located between chr18:53259508 and chr 18:53259552.

18 . The method of claim 17 , wherein detecting an increased level of methylation comprises treating the nucleic acid sample with sodium bisulfite under conditions whereby unmethylated cytosines are converted to uracil, and methylated cytosines remain unchanged and performing methylation-specific PCR (MSP) on the treated nucleic acid using at least two distinct methylation-specific primer sets for the sequence of ONECUT2.

19 . The method of claim 17 , wherein detecting an increased level of methylation of the at least one CpG island of ONECUT2 comprises reacting the nucleic acid sample with reagents for detecting the level of methylation of at least one CpG island of ONECUT2 and performing a polymerase chain reaction (PCR).

Assignees

• Univ Erasmus Med Ct Rotterdam

Inventors

• Zwarthoff Ellen Catharina
• Van Tilborg Annechiena Geertruide

Classifications

• C12Q2600/154

  Methylation markers · CPC title

• C12Q2600/16

  Primer sets for multiplex assays · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title